Related Experiment Video
Updated: Apr 14, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
A metabolomic approach to identifying platinum resistance in ovarian cancer
Laila M Poisson1,2,3, Adnan Munkarah4,5, Hala Madi6
1Center for Bioinformatics, Henry Ford Hospital, Detroit, MI, 48202, USA. lpoisso1@hfhs.org.
Background:
Acquisition of metabolic alterations has been shown to be essential for the unremitting growth of cancer, yet the relation of such alterations to chemosensitivity has not been investigated. In the present study our aim was to identify the metabolic alterations that are specifically associated with platinum resistance in ovarian cancer. A global metabolic analysis of the A2780 platinum-sensitive and its platinum-resistant derivative C200 ovarian cancer cell line was performed utilizing ultra-high performance liquid chromatography/mass spectroscopy and gas chromatography/mass spectroscopy. Per-metabolite comparisons were made between cell lines and an interpretive analysis was carried out using the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic library and the Ingenuity exogenous molecule library.
Results:
We observed 288 identified metabolites, of which 179 were found to be significantly different (t-test p < 0.05) between A2780 and C200 cells. Of these, 70 had increased and 109 had decreased levels in platinum resistant C200 cells. The top altered KEGG pathways based on number or impact of alterations involved the cysteine and methionine metabolism. An Ingenuity Pathway Analysis also revealed that the methionine degradation super-pathway and cysteine biosynthesis are the top two canonical pathways affected. The highest scoring network of altered metabolites was related to carbohydrate metabolism, energy production, and small molecule biochemistry. Compilation of KEGG analysis and the common network molecules revealed methionine and associated pathways of glutathione synthesis and polyamine biosynthesis to be most significantly altered.
Conclusion:
Our findings disclose that the chemoresistant C200 ovarian cancer cells have distinct metabolic alterations that may contribute to its platinum resistance. This distinct metabolic profile of platinum resistance is a first step towards biomarker development for the detection of chemoresistant disease and metabolism-based drug targets specific for chemoresistant tumors.
Insights
Platinum-resistant ovarian cancer cells exhibit distinct metabolic alterations, particularly in methionine and cysteine pathways. These findings may lead to new biomarkers and metabolism-based therapies for chemoresistant tumors.
Area of Science:
- Biochemistry
- Metabolomics
- Oncology
Background:
- Metabolic alterations are crucial for cancer growth but their link to chemosensitivity remains unclear.
- This study aimed to identify metabolic changes associated with platinum resistance in ovarian cancer.
- Understanding these metabolic shifts is key to overcoming treatment resistance.
Purpose of the Study:
- To identify specific metabolic alterations linked to platinum resistance in ovarian cancer.
- To compare the metabolic profiles of platinum-sensitive and platinum-resistant ovarian cancer cell lines.
- To lay the groundwork for developing biomarkers and therapeutic targets for chemoresistant ovarian cancer.
Main Methods:
- Global metabolic analysis using ultra-high performance liquid chromatography/mass spectrometry and gas chromatography/mass spectrometry.
- Comparison of 288 identified metabolites between platinum-sensitive (A2780) and platinum-resistant (C200) ovarian cancer cell lines.
- Pathway analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG) and Ingenuity Pathway Analysis.
Main Results:
- 179 out of 288 identified metabolites showed significant differences between the cell lines.
- Methionine and cysteine metabolism pathways were the most significantly altered.
- Key affected pathways included methionine degradation, cysteine biosynthesis, glutathione synthesis, and polyamine biosynthesis.
Conclusions:
- Chemoresistant ovarian cancer cells possess distinct metabolic alterations.
- These metabolic differences may contribute to platinum resistance.
- This metabolic profile is a potential basis for developing chemoresistance biomarkers and metabolism-based drug targets.
More Related Videos
11:51Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
Published on: November 18, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020